Tandem Diabetes Care, Inc.
NASDAQ:TNDMMedical - Devices
+$0.24 today
- Market cap
- $1.19B
- Beta
- 1.57
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.38
Volume 2.35M
Average 2.43M
TNDM Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Tandem Diabetes Care, Inc.NASDAQ: TNDM
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $3.76M fell 12.9% year over year, behind the -1.1% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 16.4% from the prior quarter. Over 3 fiscal years it compounded at -1.2% a year.
Context
- Depreciation & amortization amounted to 1.4% of revenue in FY2025, down 0.4 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -12.9% toward the trailing-twelve-month pace of -1.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 13.84M USD
- Year-over-year change
- -16.7%
- 4-year CAGR
- -0.0%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13.84M | -16.7% |
| FY2024 | 2024-12-31 | 16.61M | +5.7% |
| FY2023 | 2023-12-31 | 15.72M | +9.7% |
| FY2022 | 2022-12-31 | 14.33M | +3.5% |
| FY2021 | 2021-12-31 | 13.85M | — |
Depreciation & Amortization vs competitors
How TNDM compares with its peers on the latest reported figures
- TNDM's LTM Mar 2026 depreciation & amortization of $17.11M is the 4th largest of the 8 companies compared; the peer median is $15.97M.
- Its year-over-year change of -1.1% is the lowest of 7, against a peer median of +24.6%.
- Depreciation & amortization amounts to 1.7% of revenue for TNDM, versus a peer median of 4.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $264.1M | +11.9% | +17.3% | 5.3% | |
MMEDMiniMed Group, Inc. Common Stock | LTM Jul 2026 | $158M | — | +10.7% | 4.9% |
| LTM Jun 2026 | $99.3M | +14.4% | +12.7% | 3.3% | |
| LTM Mar 2026 | $17.11M | -1.1% | -1.2% | 1.7% | |
| LTM Mar 2026 | $15.97M | +59.8% | +25.0% | 4.4% | |
| LTM Mar 2026 | $2.94M | +26.6% | +11.3% | 2.7% | |
| LTM Mar 2026 | $1.48M | +102.1% | -54.8% | 3.6% | |
| LTM Mar 2026 | $1.12M | +22.5% | +35.7% | — | |
MMEDVMiniMed Group, Inc. | — | — | — | — | — |
| Peer median (excluding TNDM) | $15.97M | +24.6% | +12.7% | 4.0% | |
Competitors are the stored peer set for TNDM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 15.57M | (94.59M) | (222.61M) | (96.03M) | (204.71M) |
| Depreciation & Amortization | 13.85M | 14.33M | 15.72M | 16.61M | 13.84M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 60.75M | 84.92M | 88.08M | 101.38M | 92.38M |
| Change in Working Capital | 14.37M | (4.65M) | (17.69M) | (11.78M) | (23.04M) |
| Accounts Receivables | (30.98M) | (7.83M) | 4.28M | (20.8M) | (56.81M) |
| Inventory | (4.95M) | (42.45M) | (46.05M) | 5.81M | 24.82M |
| Accounts Payables | 10.28M | 24.49M | (4.86M) | (2.39M) | 2.23M |
| Other Working Capital | 40.03M | 21.14M | 28.96M | 5.6M | 6.73M |
| Other Non-Cash Items | 6.82M | 50.46M | 104.7M | 14.04M | 111.81M |
| Operating Cash Flow | 111.36M | 50.46M | (31.81M) | 24.23M | (9.72M) |
| Capital Expenditures | (23.51M) | (34.1M) | (26.8M) | (19.23M) | (19.95M) |
| Acquisitions (Net) | 0 | (25.72M) | (69.5M) | 0 | 0 |
| Purchases of Investments | (733.39M) | (467.65M) | (535.66M) | (264.31M) | (85.66M) |
| Sales of Investments | 570.02M | 569.49M | 546.22M | 306.46M | 257.07M |
| Other Investing Activities | (9.33M) | (8.86M) | 0 | (46.4M) | (78.59M) |
| Investing Cash Flow | (186.88M) | 33.17M | (85.74M) | (23.48M) | 72.88M |
| Debt Repayment | 0 | 0 | 0 | 44.91M | (40.76M) |
| Common Stock Issued | 0 | 17.55M | 0 | (6.73M) | (2.61M) |
| Common Stock Repurchased | 0 | 0 | 0 | (30M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 51.93M | (675K) | 4.11M | 183K | 0 |
| Financing Cash Flow | 51.93M | 16.88M | 4.11M | 8.37M | (43.37M) |
| Effect of Forex Changes | 153K | 827K | (212K) | 1.26M | 1.61M |
| Net Change in Cash | (23.43M) | 101.34M | (113.65M) | 10.37M | 21.4M |
| Free Cash Flow | 87.85M | 16.37M | (58.61M) | 4.99M | (29.67M) |
Tandem Diabetes Care, Inc.
NASDAQ:TNDM
Intrinsic Alpha fair value
Locked
Current Price
$17.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.